Inc. Magazine recently recognized Arine as one of the fastest-growing private companies in the United States. As we reflect on what this achievement represents, we celebrate the teamwork, key partnerships, and innovative solutions that have gotten us this far. We also recognize that this is just the beginning. We’re more motivated than ever to continue building our medication intelligence solutions to address the $528 billion healthcare problem with non-optimized medication.
Our growth is a testament to our ability to meet the evolving needs of our healthcare payer and at-risk provider clients who face increasing pressure to deliver outcomes for their members and manage rising costs of care.
Three things have propelled us to achieve this level of success thus far:
Being one of the first companies to meaningfully apply AI in healthcare, Arine has scaled in a way that was previously not possible. Ranking No. 5 in the AI category demonstrates how our use of artificial intelligence sets Arine apart in a healthcare landscape that is inefficient, to say the least, and that has limited tools that enable a high level of targeted and personalized care.
It is well-understood that certain members are known to have higher costs—like those with chronic conditions, those with mental health conditions, those who are elderly, and those with lower socioeconomic status, for example. This is a large pool that requires many resources to address, and only a fraction of them will respond. This makes targeting the right individuals with the appropriate outreach all the more critical for achieving outcomes at scale.
Arine uses AI-driven targeting and recommendation engines to identify 1) those individuals most in need and 2) those medication-based care recommendations which will have the greatest impact on outcomes and costs across an entire population. The resulting list of targeted members and actions leads to improved population health and reductions in cost of care beyond what is possible with a set of rules-based risk factors.
By honing in on the most critical needs with this level of precision and urgency, Arine allows care teams to deliver the right care to those who need it most, ensuring timely and effective interventions that surpass other models. Care teams can focus more time on high-value care that benefits from human connection.
By combining our AI algorithms with deep clinical expertise, Arine generates medication-based care interventions that collectively impact outcomes at the patient, provider, and population health levels. We provide recommendations that not only target traditionally high-risk members, but can also predict and intervene for those most in need among the broader pool of two-thirds of Americans who need medication to manage their health.
At the core of our clinical guidance are medication-based care interventions, which are powered by algorithms developed by Arine’s expert team of clinical pharmacists. These recommendations are rooted in the latest clinical guidelines and evidence-based research, ensuring that each patient is on the optimal medication regimen to achieve the desired outcomes across disease states.
With a comprehensive view of each member's data, including clinical, social, and behavioral factors, our clinical algorithms identify and mitigate risks associated with non-optimized medication therapy. These include adherence, drug-related problems, polypharmacy, and drug-drug interactions. Our recommendations are also continuously updated with the latest clinical guidance, fostering trust with the providers whose members we are managing. We offer a truly whole-person care solution rooted in robust clinical data to rein in the billions of dollars wasted as a result of non-optimized medications.
At Arine, we can predict which medication-based care interventions will drive the best outcomes and the lowest costs, in turn allowing our health plan partners to accelerate their own progress toward these value-based care goals. This is why Arine has been able to gain traction with national health plans across their Commercial, Medicare, and Medicaid lines of business, achieving an impressive 100% client retention rate. On average, we save health plans more than ten percent in total cost of care for the members we intervene on, and drive a more than forty percent reduction in emergency department utilization.
With outcomes and cost savings as the ultimate goals, Arine’s medication-based care recommendations target the most impactable members in the high-risk groups that you would expect (like people with heart failure or diabetes) but also identify any individuals with non-obvious risk for poorer outcomes and higher costs. These risks include the combination of drugs the patient is on, medical or behavioral diagnoses, or medication changes associated with high-cost events.
Arine’s health outcomes team then deploys rigorous, validated methods for associating the reductions in cost of care to specific patient-level interventions. These learnings inform and strengthen our AI-powered models and platform over time. Evaluating the impact of over 40 million recommendations allows us to better predict which interventions will result in the best clinical improvements across a diverse population—and the associated dollars saved.
The result is Arine’s outcomes-focused platform that is optimized for true value-based care: improved outcomes AND lower costs.
Arine’s rapid growth reflects the increasing recognition across health plans that medication intelligence is critical to achieving value-based care goals. This shift indicates that Arine’s strategies are not only capable of driving outcomes at scale but are also instrumental in achieving meaningful cost savings across member populations.
See our press release for more information about Inc. 5000 and Arine's recognition as one of America's fastest-growing companies.